Table I.
A summary of the reported use of Janus kinase inhibitors to treat cutaneous and systemic sarcoidosis
| Drug | JAKs | Dose | n | Δ Cutaneous? | Δ Systemic? | Disease duration | Fitzpatrick type | Sex | Country | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| Oral JAK inhibiton | ||||||||||
| Tofacitinib | JAK1/2/3 | 5 mg twice daily | 1 | CR | N/A | 8 y | II | F | United States | Damsky et al4 |
| Tofacitinib | JAK1/2/3 | 5 mg twice daily | 3 | CR (3) | N/A | 6-25 y | VI | 2 F, 1 M | United States | Damsky et al5 |
| Tofacitinib | JAK1/2/3 | 5-10 mg twice daily | 1 | CR | CR | 21 y | I | F | United States | Damsky et al6 |
| Tofacitinib | JAK1/2/3 | 2.5-16 mg daily | 5 | CR/NCR (3), PR (2) | PR (3), N/A (2) | Not reported | White | F | Australia | Kerkemeyer et al8 |
| Tofacitinib | JAK1/2/3 | 5 mg twice daily | 5 | N/A | PR (3), N/A (2) | 1-5 y | 4 Caucasian, 1 African American | 4 M, 1 F | United States | Friedman et al9 |
| Ruxolitinib | JAK1/2 | 5 mg twice daily | 1 | CR | NCR | 18 y | European anscestry | F | France | Rotenberg et al10 |
| Ruxolitinib | JAK1/2 | 10 mg twice daily | 1 | CR | PR | 1 y | VI | F | United States | Wei et al11 |
| Ruxolitinib | JAK1/2 | 20 mg daily | 1 | N/A | CR | 5 y | Not reported | F | France | Levraut et al12 |
| Baricitinib | JAK1/2 | 4 mg daily | 1 | N/A | CR | 10 wk | Not reported | F | Brazil | Scheinberg et al13 |
| Topical JAK inhibition | ||||||||||
| Tofacitinib | JAK1/2/3 | 2% ointment twice daily | 1 | PR | N/A | 5 y | II | F | United States | Singh et al14 |
| Tofacitinib | JAK1/2/3 | 2% ointment twice daily | 1 | PR | N/A | 9 y | VI | M | United States | Alam et al15 |
CR, Complete response; F, female; JAK, Janus kinase; M, male; N/A, not applicable; NCR, near complete response; PR, partial response.